±¹³»¿Ü Ç÷¾×ÇÐ ±ÇÀ§ÀÚµéÀÇ ÇмúÀÜÄ¡¸¦ ÅëÇØ »õ·Î¿î Ç÷¿ìº´Ä¡·á¹ý¿¡ ´ëÇÑ ¿¬±¸°¡ ÁýÁß Á¶¸í¹Þ°Ô µÇ¾ú´Ù.
´ëÇÑÇ÷¾×ÇÐȸ(ȸÀå ¹ÚÂùÁ¤)´Â 3¿ù 14ÀϺÎÅÍ 16ÀϱîÁö ¼¿ï ±×·£µå¿öÄ¿ÈúÈ£ÅÚ¿¡¼ '±¹Á¦Ç÷¾×ÇÐÄÁÆÛ·±½º'(iCKSH=Korean Society of Hematology International Conference)¸¦ °³ÃÖÇÑ´Ù. Ç÷¾×ÇÐȸ´Â ¿¬°£ 2ȸ Çмú´ëȸ¸¦ ¿¾î¿À°í Àִµ¥, À۳⿡ ÀÌ¾î ¿ÃÇØ Ãá°è Çмú´ëȸ¸¦ ±¹Á¦´ëȸ·Î À¯Ä¡ÇÏ¸é¼ ³ª¶ó ¾ÈÆÆÀÇ Àú¸íÇÑ Ç÷¾×ÇÐ Àü¹®°¡µéÀÇ Çмú°¿¬°ú ȸÀǸ¦ ±âȹÇÑ °ÍÀÌ´Ù.
ƯÈ÷ À̹ø ÄÁÆÛ·±½º¿¡´Â Ç÷¿ìº´¿¡ °üÇÑ °¿¬ÀÌ ¼¼ Â÷·ÊÀÇ ¼¼¼Ç¿¡ °ÉÃÄ ¹èÄ¡µÊÀ¸·Î¼ Ç÷¿ìº´À» ÇâÇÑ ÇаèÀÇ °ü½ÉÀ» Àß º¸¿©ÁÖ°í ÀÖ´Ù.
|
|
|
¡ã 'Ç÷¾×Áúȯ¿¡¼ Å©¸®½ºÆÛ À¯ÀüÀÚ°¡À§ ±â¼úÀÇ Àû¿ë', 'Ç÷¿ìº´ À¯ÀüÀÚÄ¡·á-Ç÷¿ìº´ Ä¡·áÀÇ »õ·Î¿î ¿µ¿ªÀΰ¡?' °¿¬ÀÌ ¿¹Á¤µÈ 'Gene Therapy in Hematology' ¼¼¼Ç |
¸ÕÀú ù°³¯(14ÀÏ) ¿ÀÀü 10½Ã45ºÐ¿¡´Â ¡âÇ÷¾×Áúȯ¿¡¼ Å©¸®½ºÆÛ À¯ÀüÀÚ°¡À§ ±â¼úÀÇ Àû¿ë(Application of CRISPR/Cas-9 in blood disease)À̶ó´Â ÁÖÁ¦·Î ¸ÅÆ© Æ÷Åõ½º ±³¼ö(Matthew H. Porteus / ½ºÅÄÆ÷µå ÀÇ´ë)ÀÇ °¿¬°ú ¡âÇ÷¿ìº´ À¯ÀüÀÚÄ¡·á-Ç÷¿ìº´ Ä¡·áÀÇ »õ·Î¿î ¿µ¿ªÀΰ¡?(Gene therapy for hemophilia-will there be a new era in hemophilia treatment?)¸¦ ÁÖÁ¦·Î ÇÑ Ä³¼¸° ÇÏÀÌ ¹Ú»ç(Katherine Ann High / ½ºÆÄÅ© ¼¼¶óǻƽ½º) °¿¬ÀÌ ÁغñµÇ¾î ÀÖ´Ù. ÀÌ Áß Ä³¼¸° ÇÏÀÌ ¹Ú»ç´Â ÇöÀç ±Û·Î¹ú ÈÀÌÀÚ»ç¿Í ÇÔ²² Ç÷¿ìº´ 9ÀÎÀÚ À¯ÀüÀÚÄ¡·á¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀ» 8³â° ¼º°øÀûÀ¸·Î À̲ø°í ÀÖ´Â ½ºÆÄÅ©»çÀÇ R&D ÃÖ°íÃ¥ÀÓÀÚ·Î ¾Ë·ÁÁ® ÀÖ´Ù.
|
|
|
¡ã 'Ç÷¿ìº´ A, B À¯ÀüÀÚÄ¡·áÀÇ ¹ßÀü', '°³ÀÎ ¸ÂÃãÇü Ç÷¿ìº´Ä¡·á : ´ëÁßÀû ¾àµ¿·ÂÇÐÀÇ Á¢±Ù' °¿¬ÀÌ ¿¹Á¤µÈ 'Bleeding Disorder/Thrombosis' ¼¼¼Ç
|
À̾î À̳¯ ¿ÀÈÄ 4½Ã 40ºÐºÎÅÍ´Â ¡âÇ÷¿ìº´ A, B À¯ÀüÀÚÄ¡·áÀÇ ¹ßÀü(Progress in gene therapy for hemophilia A and B)À̶ó´Â ÁÖÁ¦·Î Çѱ¹ Ç÷¿ì»çȸ¿¡µµ Àß ¾Ë·ÁÁø ±Û·» ÇǾ ¹Ú»ç(Glenn Pierce / ¼¼°èÇ÷¿ì¿¬¸Í)ÀÇ °¿¬°ú ¡â°³ÀÎ ¸ÂÃãÇü Ç÷¿ìº´Ä¡·á : ´ëÁßÀû ¾àµ¿·ÂÇÐÀÇ Á¢±Ù(Individualized treatment for hemophilia: Population pharmacokinetics approach)À» ÁÖÁ¦·Î ½Åµð À¶ ±³¼ö(Cindy H. T. Yeung / ¸Æ¸¶½ºÅÍ ´ëÇÐ)ÀÇ °¿¬ÀÌ Æ÷ÁøµÇ¾î ÀÖ´Ù. ÀÌ Áß ±Û·» ÇǾ ¹Ú»ç´Â º»ÀÎÀÌ Ç÷¿ìº´ ȯÀÚÀÎ µ¿½Ã¿¡ ÇöÀç ¼¼°èÇ÷¿ì¿¬¸Í(WFH) ¹× WFHUSA ÀÌ»çȸ¿Í ¹Ì±¹Ç÷¿ìº´Àç´Ü(NHF) ÀÇ·á ¹× °úÇÐ ÀÚ¹®À§¿øÀ» ¸Ã°í ÀÖÀ¸¸ç Third Rock VenturesÀÇ Àü¼Ó ±â¾÷°¡ÀÌÀÚ À¯ÀüÀÚÄ¡·á ¹× Ç÷¾×ÇÐ ºÐ¾ßÀÇ »ý¸í°øÇÐ ÄÁ¼³ÅÏÆ®ÀÌ´Ù.
|
|
|
¡ã 2018³â ½ºÄÚƲ·£µå¿¡¼ ¿¸° ¼¼°èÇ÷¿ì¿¬¸ÍÃÑȸ¿¡¼ À¯ÀüÀÚÄ¡·á¿¡ ´ëÇÑ °¿¬ ÈÄ Çì¸ð¶óÀÌÇÁ ÃëÀçÁø°ú ÀÎÅͺäÇÏ°í ÀÖ´Â ±Û·» ÇǾ ¹Ú»ç |
¶ÇÇÑ ÀÌƲ°ÀÎ 15ÀÏ ¿ÀÈÄ 4½Ã 35ºÐ¿¡´Â ÄÉÀÌÁö ³ë°¡¹Ì ±³¼ö(Keiji Nogami / ³ª¶ó ÀÇ´ë)ÀÇ ¡âÇ÷¿ìº´ Ä¡·á¿¡¼ÀÇ Ç÷Àü ÆÄÇü ºÐ¼® ÀÓ»ó Àû¿ë(Clinical application of clot waveform analysis in hemophilia treatment) °¿¬ÀÌ ÁغñµÇ¾î ÀÖ´Ù.
ÇÑÆí, À̹ø ±¹Á¦Ç÷¾×ÇÐÄÁÆÛ·±½ºÀÇ ¸ÞÀνºÆù¼·Î´Â ¾ÏÁ¨, BMS, ´ÙÄÉ´Ù, ±³¿Í±â¸°, ³ë¹ÙƼ½º, ·Î½´ µî ±Û·Î¹ú ±¼ÁöÀÇ Á¦¾àȸ»çµéÀÌ Âü¿©ÇÏ°í ÀÖ°í, GC³ì½ÊÀÚ, »ç³ëÇÇ, ³ëº¸³ëµð½ºÅ©, »þÀ̾î, SKÁ¦¾à, ÈÀÌÀÚ µî ±¹³» Ç÷¿ìº´ Ä¡·áÁ¦¸¦ °ø±ÞÇÏ°í Àִ ȸ»çµéµµ ½ºÆù¼·Î Æ÷ÇԵǾî Ç÷¿ì»çȸÀÇ ¶ß°Å¿î °ü½ÉÀ» ¹Ý¿µÇÏ°í ÀÖ´Ù.
Çì¸ðÇʸ®¾Æ¶óÀÌÇÁ¿¡¼´Â 2019 iCKSH¿¡¼ÀÇ ÇöÀåÃëÀ縦 ÅëÇØ ÃâÇ÷Áúȯ °ü·Ã µû²öÇÑ Ä¡·áµ¿Çâ°ú °ü°èÀÚ ÀÎÅͺ並 »ó¼¼ÇÏ°Ô ÀüÇÒ ¿¹Á¤ÀÌ´Ù.
|
|
|
¡ã 2019 ±¹Á¦Ç÷¾×ÇÐÄÁÆÛ·±½ºÀÇ ½ºÆù¼µé |
[Çì¸ð¶óÀÌÇÁ ±èÅÂÀÏ ±âÀÚ]
< ÀúÀÛ±ÇÀÚ © Çì¸ðÇʸ®¾Æ ¶óÀÌÇÁ ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |